Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

AbbVie’s hotly anticipated psoriasis drug Skyrizi (risankizumab) has been approved in Japan, the first country to okay this potential blockbuster. Skyrizi is important for AbbVie as sales of its ...

Several medications now calm painful inflammation in the intestines. Diets free of ultraprocessed foods also help ...

Skyrizi (risankizumab) and Rinvoq (upadacitinib). Skyrizi is an interleukin-23 (IL-23)-inhibiting monoclonal antibody while Rinvoq is a small molecule Janus kinase (JAK) inhibitor. The company is ...

In May 2024, the CHMP granted a positive recommendation for AbbVie’s ulcerative colitis drug Skyrizi (risankizumab). "CHMP recommends AbbVie’s Rinvoq be approved for adult GCA" was originally created ...

The positive growth drivers offsetting this loss included Skyrizi (risankizumab), an IL-23-targeted mAb used across a range of immunology indications such as psoriasis, and Rinvoq (upadacitinib ...

In terms of competition, there are currently only two other IL-23 inhibitors approved in the US besides Tremfya – Eli Lilly’s Omvoh (mirikizumab) and AbbVie’s Skyrizi (risankizumab).